Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 22;12(3):e01434-21. doi: 10.1128/mBio.01434-21

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Sooryanarain et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

PMC Copyright notice

FIG 8 — Loss of PGRMC1/2 by siRNA knockdown during progesterone treatment increased the levels of HEV-induced IFN-λ1 expression via ERK. (A) Experimental regimen. (B) Fold change in IFN-λ1 mRNA levels in various conditions tested. (C and D) Western blot analysis of phosphorylated ERK (pERK) and total ERK (tERK) levels during progesterone treatment. (C) PGRMC1/2 knockdown cells. (D) ERK inhibitor U0126 (U01) treated cells. (E) Fold change in IFN-λ1 mRNA levels in the presence or absence of ERK inhibitor U0126 (U01). The data represent an average ± SEM of 2 independent experiments; Student’s t test, N.S, nonsignificant; siCnt, scramble control siRNA transfected cells; siPGRMC1 + 2, PGRMC1/2 siRNA transfected cells; U01, 10 μM ERK inhibitor U0126; 80 nM PRO = 25 ng/ml progesterone final concentration.